Meta-analysis Results of Myocarditis Following COVID-19 Vaccination in 4 Nordic Countries Myocarditis in Females Within 28 Days Following SARS-CoV-2 VaccinationĮFigure 2. Mortality and Discharge Outcomes Among Myocarditis CasesĮFigure 1. Distribution of Comorbidities for Total Population at Start of Follow-up and for Myocarditis Cases, by Vaccination Status Nordic Countries Denmark, Finland, Norway, and Sweden CombinedĮTable 11. Days From Vaccination to Date of Admission for Vaccinated Myocarditis CasesĮTable 10. Myocarditis Within 7 Days Following a Dose of SARS-CoV-2 Vaccine, According to Sex and AgeĮTable 9. Myocarditis Within 28 Days of a Positive SARS-CoV-2 Test, According to Sex and AgeĮTable 8. Myocarditis and Pericarditis Combined Within 28 Days Following a Dose of SARS-CoV-2 Vaccine, Boys 12-15 yearsĮTable 7. Myocarditis, Pericarditis, and Myocarditis and Pericarditis Combined Within 28 Days Following a Dose of SARS-CoV-2 Vaccine, According to Sex and Age, and Model for AdjustmentĮTable 6. Pericarditis Within 28 Days Following a Dose of SARS-CoV-2 Vaccine, According to Sex and AgeĮTable 5. Number of Persons Vaccinated by CountryĮTable 4. Definition of Covariates per CountryĮTable 3. Definition of Myocarditis and Pericarditis Outcome and WashoutĮTable 2. Descriptions of Data Sources, Washout Period, Outcome Events, and Ethical RegulationsĮTable 1.
0 Comments
Leave a Reply. |